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ABSTRACT  
More complications and cost of promoting of imaginative drugs are more prominent consideration to the improvement of controll ed release 
(CR) drug delivery systems. Sustained release or controlled release drug delivery system helps to reduced toxicity of drug and mor e patient 
compliant drug delivery system. The aim of this study is to have efficient means of manufacturirng of Gastro retentive floating tablet of 
Atorvastatin Calcium. Atorvastatin is used in the treatment of hyperlipidaemia. Oral bioavailability of atorvastatin calcium is less than 12% due 
to instability and in complete absorption. It also undergoes high first pass metabolism. It is absorbed more in the upper part of the GIT. Gastro 
retentive drug delivery system of Atorvastatin enhanced the bioavailability by retaining the drug in upper part of GIT and by  preventing the 
first pass metabolism of the drug. The objective of present work was to create and assessed oral extended release gastro retentive tablet dosage 
form of Atorvastatin by using direct compression method using Methocel K4MDC2, Methocel K100MDC2 and Glyceryl behenate using Statistical 
design (JMP software). Sodium bicarbonate and Citric Acid is used as gas generating agent which helps to float the tablet.  
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INTRODUCTION: 
The oral route of drug administration is the most important 
strategy of regulating the drug for systemic impact. To attain 
and keep up the concentration of managed drug within 
therapeutically viable range, it is frequently necessary to 
take drug dosage a few times and this result in fluctuating 
levels in plasma. Controlled drug delivery systems have been 
presented to overwhelm the downsides of fluctuating levels 
associated with traditional dosage form1. 
Gastro retentive drug delivery system (GRDDS) is novel site-
specific drug delivery for advancing maintenance of drug 
within the stomach, duodenum or small intestine can drag 
out drug released to controlled manner. The oral 
administration approaches to realize prolong discharge of 
drug is the utilize of gastro-retentive frameworks. The 
thought is to prolong the home time of the drug release 
within the stomach known as gastric home time (GRT)2 
GRDDS expand essentially the term of time over which the 
drugs may be released. They not as it were draw out dosing 
interims, but moreover increment quiet compliance past the 
level of existing controlled release dosage form. Control 
release suggests the consistency and reproducibility to 
control the drug release, drug concentration in target tissue 
and optimization of the restorative impact of a drug by 
controlling its release within the body with lower and less 
visit measurements3,4 
Controlling the home time of drug delivery system in a 
specific locale of GI tract can be achieved by a few 
approaches, muco adhesive system, super permeable 
hydrogels and expandable system and drifting drug release5 
Choice of excipients is a critical strategic decision for 
planning a dosage form with consistence and controlled 
release in the stomach. Water dissolvable cellulose 
derivatives represent a normal lesson of polymers best 
suited for such purposes. It has been proposed that higher 
molecular weight polymers and slower rates of polymer 
hydration are ordinarily related with better drifting 
behavior. In this manner, tall molecular weight and less 
hydrophilic polymers are expected to improve floating 
properties of delivery systems6 
Effervescent drifting drug delivery systems are the network 
sort systems formulated with the assistance of swellable 
polymers such as hydroxyl propyl methyl-cellulose with 
various effervescent components like sodium bicarbonate   
and citric acid. Such dosage forms once interacted with 
gastric fluid then carbon dioxide liberated, and it helps the 
swollen matrix to float in stomach and release the drug at 
specific site in control manner7,8 
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The point of the work is to create a Gastroretentive floating 
drug delivery tablet of atorvastatin calcium by effervescence 
strategy. The objective behind the study was to analyze the 
impact of concentration of Methocel polymers and glyceryl 
behenate, concentration of sodium bicarbonate and citric 
acid on the release of atorvastatin calcium utilizing 
Statistical design. 
MATERIALS AND METHODS: 
Materials: 
Atorvastatin Calcium was obtained as a gift sample from 
Rubicon Research, Mumbai. Hydroxy propyl methyl cellulose 
(HPMC K4M DC2 & K100M DC2) and Starch 1500 was 
obtained from Colorcon Asia Bio limited. (India). Citric acid, 
Magnesium stearate, Sodium bicarbonate, were obtained 
from Perrigo Laboratories as gift sample. Glyceryl behenate 
(Compritol 888 ATO) obtained from Gattefosse, Mumbai. All 
other ingredients used for analytical method were analytical 
grade material. 
Method:  
Different formulation composition is determined using 
Custom design using JMP software (version 13).and batches 
prepared accordingly. 
Extended release floating tablets of Atorvastatin were 
prepared by direct compression method. Weighed 
accurately quantity of all the excipients and drug 
Atorvastatin Calcium. Sifted all raw materials through mesh 
20# ASTM. Atorvastatin and Glyceryl behenate mixed in V-
shell blender for 15 minutes. Added other excipients such as 
HPMC K4MDC2, HPMCK100M DC2, Starch 1500, Citric Acid 
and Sodium bicarbonate and mixed for 30 minutes in V-
blender and lubricated the blend with sifted magnesium 
stearate for 5 minutes in V-blender. Then lubricated blend 
was feed in hopper and tablets were prepared by direct 
compression using multi station rotatory punching machine. 
The tablets were prepared using the punch of 10 mm 
diameter using the rotary tablet processing machine. 
Each formulation was composed of drug and excipients in 
various proportions as shown in Table1 and Table 2: 
Table 1: Formulation details for F1to F6 
Ingredients F1 F2 F3 F4 F5 F6 
Atorvastatin Calcium 86.76 86.76 86.76 86.76 86.76 86.76 
Glyceryl Behenate 43.00 43.00 43.00 43.00 43.00 43.00 
Methocel K4MDC2 80.00 100.00 80.00 120.00 120.00 80.00 
Methocel K100M DC2 140.00 120.00 100.00 100.00 140.00 100.00 
Starch 1500 25.00 25.00 25.00 25.00 25.00 25.00 
Sodium bicarbonate 20.00 30.00 30.00 30.00 30.00 30.00 
Citric Acid anhydrous 15.00 10.00 10.00 10.00 10.00 10.00 
Microcrystalline Cellulose PH 102 85.24 80.24 120.24 80.24 40.24 120.24 
Magnesium Stearate 5.00 5.00 5.00 5.00 5.00 5.00 
Total  500.00 500.00 500.00 500.00 500.00 500.00 
 
Table 2: Formulation details for F7 to F12 
Ingredients F7 F8 F9 F10 F11 F12 
Atorvastatin Calcium 86.76 86.76 86.76 86.76 86.76 86.76 
Glyceryl Behenate 43.00 43.00 43.00 43.00 43.00 43.00 
Methocel K4MDC2 100.00 120.00 80.00 80.00 120.00 80.00 
Methocel K100M DC2 120.00 100.00 100.00 140.00 140.00 140.00 
Starch 1500 25.00 25.00 25.00 25.00 25.00 25.00 
Sodium bicarbonate 30.00 30.00 30.00 30.00 30.00 30.00 
Citric Acid anhydrous 10.00 10.00 10.00 10.00 10.00 10.00 
Microcrystalline Cellulose PH 102 80.24 80.24 120.24 80.24 40.24 80.24 
Magnesium Stearate 5.00 5.00 5.00 5.00 5.00 5.00 
Total  500.00 500.00 500.00 500.00 500.00 500.00 
 
Characterization of Atorvastatin Floating Tablet: 
Pre-compression studies9: 
Evaluation final mix/blend were carried out to check the 
flow properties of blend includes angle of repose, bulk 
density and tapped density, compressibility index and 
Hausner's ratio. 
Angle of Repose: 
This is the angle between the horizontal plane and surface of 
a pile of blend. It was determined by using the funnel 
method. The weighed final mix/blend was taken in the 
funnel. The altitude of the funnel adjusted to the maximum 
cone height (h) and final mix/blend was poured through the 
funnel freely on to the surface. Then the radius of the heap 
(r) was measured and angle of repose was calculated. The 
diameter of the granule cone will be measured and then the 
angle of repose. 
Tan Ѳ= h/r 
Bulk density (BD): 
50 g of final mix/ blend was introduced to a measuring 
cylinder of 250 ml. The volume occupied by the powder was 
measured which gave bulk volume. The bulk density of 
blend was determined using the following formula. 
Bulk Density = Total weight of blend / Total volume of blend 
Tapped density (TD): 
The measuring cylinder was tapped until no further change 
in volume was noted which gave the tapped volume. The 
tapped density of blend blends was determined using the 
following formula. 
Tapped density = Total weight of blend / Total volume of 
blend after tapped 
Patil et al                                                                                                                    Journal of Drug Delivery & Therapeutics. 2019; 9(4-A):19-25 
ISSN: 2250-1177                                                                                  [21]                                                                                 CODEN (USA): JDDTAO 
Compressibility/Carr’s Index: 
Compressibility / Carr’s index was calculated by below 
formula 
Carr’s Index (%) = (Tapped density – Bulk density ) / 
(Tapped density) x 100 
Hausner’s ratio 
It is the measurement of frictional resistance of the final 
mix/blend. The ideal range should be 1.2-1.5, it was 
determined by the ratio of tapped density and bulk density. 
HR = Tapped Density/ Bulk Density 
Post Compression Parameters:  
All batches were evaluated for different tableting 
parameters as follows; 
Weight Variation:  
Twenty tablets from each batch were selected randomly and 
their average weight was calculated. Then individual weight 
of each tablet was determined using analytical weighing 
balance and was compared with average weight. 
Hardness: 
Tablet hardness was measured by using Dr. Schleuniger 
hardness tester. From each batch 10 tablets were measured 
for the hardness and average of 10 values was noted along 
with standard deviations.  
Thickness:  
Ten tablets from the representative sample from each batch 
were randomly taken and individual tablet thickness was 
measured by using digital Vernier caliper. 
Friability test: 
For all batche friability were evaluated, Fifteen (15) tablets 
were accurately weighed and placed in the friability test 
apparatus. Apparatus was rotated for 100 rpm at the rate at 
25 rpm per minute and tablets. The tablets were then taken 
reweighed. The friability was calculated as the percentage 
weight loss. 
% friability = (Initial weight – Final weight after rotation) / 
(Initial weight) x 100 
Drug Content:  
10 tablets were weighed and powdered in mortar and pestle. 
A quantity equivalent to 100 mg of Atorvastatin calcium was 
taken in a 100 ml volumetric flask and dissolved in small 
volume of Acetonitrile and made up the volume with 0.1N 
HCL and filtered using 0.45µ filter. An aliquot of 10 ml was 
pipetted out into 100 ml volumetric flask and made up the 
volume with diluent (0.1N HCl).  Absorbance was read at 
244 nm using 0.1N HCL as a blank. 
Floating Lag time: 
Floating lag time were evaluated to check the time taken by 
the dosage form to float on the top of the dissolution 
medium. The time required for the dosage form to rise to the 
surface and float is called as floating lag time10 
Total Floating time: 
The time for which the dosage form floats on the dissolution 
medium is termed as floating time. All the formulations 
constantly floated on dissolution medium for varied period 
of time. 
In-vitro drug release study: 
In vitro dissolution study of atorvastatin calcium tablets was 
carried out in USP Dissolution apparatus type II in 900 ml 
0.1 N HCl (pH 1.2), temperature maintained at 37± 0.5ºC 
with a speed of 75 rpm. Samples of 10 ml were withdrawn 
from the dissolution apparatus at pre-determined intervals 
i.e. 30 min, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr and 10 hr and 
analyzed using HPLC instrument at wavelength 244 nm. 
Statistical Evaluation of Data: 
Statistical evaluation of the data was determined with the 
help of JMP Software (Version: 13) The models were 
generated for all the response variables using multiple linear 
regression analysis. 3D response plots were constructed 
using JMP software. 
RESULTS AND DISCUSSION: 
Physical characterization of final blend: 
The powder blend was check through different evaluation to 
asses flow properties of final mix/blend. Bulk density of 
powder blend was found between 0.490 to 0.538 g/mL, and 
tapped density ranged between 0.602 to 0.649 g/mL, Carr's 
index was found to be in the range of 15.43 to 21.67. 
Hausner's ratio values for all the formulations were found to 
be about 1.182 to 1.277. And angle of repose was found to be 
in the range of 23.25 to 27.85. The values all physical 
evaluation of blend, indicating good flow of the final 
mix/blend. Table 3 shows all batches results 
 
Table 3: Physical Characterization of final blend: 
Formulation 
Bulk Density 
(g/mL) 
Tapped Density 
(g/mL) 
Carr’s Index 
(%) 
Hausner Ratio Angle of Repose 
F1 0.510 0.617 17.35 1.210 24.45 
F2 0.521 0.625 16.67 1.200 25.90 
F3 0.532 0.629 15.43 1.182 23.25 
F4 0.513 0.629 18.46 1.226 26.50 
F5 0.493 0.629 21.67 1.277 27.50 
F6 0.538 0.649 17.20 1.208 23.50 
F7 0.515 0.629 18.04 1.220 20.10 
F8 0.510 0.621 17.86 1.217 25.80 
F9 0.535 0.637 16.04 1.191 23.25 
F10 0.518 0.621 16.58 1.199 24.85 
F11 0.490 0.602 18.63 1.229 27.85 
F12 0.508 0.613 17.26 1.209 25.25 
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Evaluation of compressed tablets: 
Compressed tablets were evaluated for different physical 
characterization such as weight variation, hardness, 
friability, thickness. Table 4 comprises all batches post 
compression parameters results. 
 
Table 4: Compressed Tablet evaluation: 
Formulation 
Weight variation 
(mg) 
Hardness (SCU) Thickness (mm) Friability (%) 
Drug Content 
(%) 
F1 500 ± 9 21.5 5.27 0.21 99.6 
F2 500 ± 8 22.7 5.32 0.23 99.0 
F3 500 ± 8 20.4 5.40 0.24 98.5 
F4 500 ± 12 22.1 5.28 0.18 100.1 
F5 500 ± 10 21.9 5.33 0.22 98.6 
F6 500 ± 11 22.8 5.40 0.17 99.4 
F7 500 ± 8 20.4 5.52 0.19 100.3 
F8 500 ± 13 23.5 5.31 0.21 99.9 
F9 500 ± 12 19.8 5.28 0.27 98.8 
F10 500 ± 10 20.9 5.25 0.22 98.6 
F11 500 ± 9 22.7 5.37 0.18 100.1 
F12 500 ± 11 20.9 5.26 0.26 98.7 
 
Table 5: Floating behavior of Tablet 
Formulation 
Floating lag time in seconds (n=3) Total Floating time  
(hr:min) 
F1 83 7:15 
F2 81 7:35 
F3 61 6:50 
F4 90 8:05 
F5 127 9:30 
F6 66 6:40 
F7 71 7:45 
F8 94 8:25 
F9 63 6:40 
F10 77 7:10 
F11 123 9:45 
F12 79 7:20 
 
In-vitro dissolution study 
The tablets were evaluated for in vitro dissolution studies in 0.1N HCl for 1 hours. Drug release of all formulation shown in 
Table 6 and Table 7 
Dissolution condition: 0.1N HCl, 900 mL, Type II, 75 RPM, temperature at 37± 0.5ºC 
Table 6. Percentage drug release of Atorvastatin floating tablet 
Time 
F1 F2 F3 F4 F5 F6 
% drug released 
30 min 14 12 17 13 8 16 
1 hr 26 22 31 23 18 29 
2 hr 35 32 39 34 31 40 
3 hr 41 40 42 48 39 49 
4 hr 52 55 58 61 49 66 
6 hr 68 69 67 71 65 78 
8 hr 79 77 80 82 75 81 
10 hr 91 95 92 89 94 95 
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Table 7. Percentage drug release of Atorvastatin floating tablet 
Time 
F7 F8 F9 F10 F11 F12 
% drug released 
30 min 12 12 18 18 8 16 
1 hr 23 24 33 28 19 28 
2 hr 39 37 38 39 29 38 
3 hr 50 49 50 42 40 46 
4 hr 62 63 65 55 50 59 
6 hr 73 71 72 68 61 67 
8 hr 84 86 86 80 77 81 
10 hr 94 92 93 90 93 93 
 
 
Figure 1: Dissolution profile of Formulation F1 to F12 
Statistical Evaluation using JMP software: 
Three-dimensional surface plot:  
   
Figure 2: Three-dimensional surface of % cumulative drug release at 1 hr, 4hr and10 hr as a function of formulation variables. 
Response plot as a function of Formulation variables  
   
Figure 3: Response plot Actual vs Predicted as a function of formulation variables. 
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Figure 4: Contour profile of Formulation F5 and F11 having Methocel K4M DC2 is 120mg and Methocel K100M DC2 is 140 mg 
Response plot (Actual vs Predicted), Contour plot shows 
formulation F5 and F11 (Methocel K4M DC2 120mg and 
Methocel K100M DC2 140 mg) looks to be optimized 
formulation.  
ANOVA was applied using on the % cumulative drug release 
to study the fitting and significations of model in Table 8
Table 8: ANNOVA table 
 Degree of 
Freedom 
Sum of squares Mean Square F ratio F significance 
Model 3 213.45 71.15 2.84 0.0105 
Residual 8 23.21 2.90 - - 
Total 11 236.67 - - - 
F-test was carried out to compare the regression mean square with the residual mean square. The ratio F is 2.84 shows model 
to be significant. 
Drug release kinetic studies: 
The release profile of optimized batch (F5 & F11) of 
Gastroretentive floating tablet of Atorvastatin fitted best to 
First Order Model (0.997 and 0.994). Thus, it may be 
concluded that Atorvastatin drug release from 
Gastroretentive floating tablet is best explained by First 
order model. 
 
Table 9: Regression analysis data 
Batch 
Zero Order First Order Korsemeyer Peppas Higuchi 
R2 R2 R2 R2 
F5 0.975 0.997 0.881 0.969 
F11 0.959 0.994 0.881 0.973 
 
 
CONCLUSION:  
Atorvastatin calcium Gastroretentive floating tablets were 
successfully prepared by direct compression method using 
statistical design (JMP software). The combination of 
Methocel K4M DC2 (24%, 120mg/tablet) and Methocel 
K100M DC2 (28%, 140mg) with sodium bicarbonate (6%) 
and Citric acid anhydrous (2%) was found to achieve 
optimum in vitro release (drug release at 1 hour below 20% 
which ensures no dose dumping, release at 4 hours shows 
half of drug released and at 10 hour ensures complete 
release of drug). In vitro release data were fitted to various 
kinetic models and drug release predominantly follows First 
Order model. 
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